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Purpose: We aimed to compare the local control rates between miriplatin and epirubicin in 
lipiodol-based transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC).
Patients and methods: Patients who underwent targeted TACE using miriplatin (47 patients, 
66 lesions) or epirubicin (64 patients, 79 lesions) as the sole therapy were enrolled. The local 
control rates were compared using the Kaplan–Meier estimator with the log-rank test. The 
patient and tumor parameters were subjected to univariate and multivariate analyses using the 
Cox proportional hazards model.
Results: The overall local recurrence rates were 39.3% and 31.6% for the miriplatin and 
  epirubicin groups, respectively. The local control rate was significantly higher in the epirubicin 
group than in the miriplatin group (P , 0.001). The local control rates at 6 months and 1 year 
were 70.7% and 44.8% for the miriplatin group and 83.4% and 69.2% for the epirubicin group, 
respectively. Multivariate analysis showed that the serum α-fetoprotein level $ 20 ng/mL (hazard 
ratio 2.96; P , 0.001), miriplatin usage (hazard ratio 2.53; P = 0.002), and Child-Pugh class B 
(hazard ratio 1.89; P = 0.042) affected local progression.
Conclusion: Lipiodol-based targeted TACE using miriplatin had inferior local control rates 
as compared to epirubicin in patients with HCC.
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Introduction
Transarterial chemoembolization (TACE) is an established local therapy for managing 
unresectable hepatocellular carcinoma (HCC) in patients with advanced cirrhosis 
and confers significant survival benefits.1,2 Iodized oil is usually used as a carrier 
of most anticancer agents to achieve preferential uptake and persistent deposit of 
the chemotherapeutic agent within the HCC nodules in conventional TACE. Most 
anticancer agents used in TACE are hydrophilic and usually prepared as emulsions 
mixed with iodized oil before intraarterial administration.3 These hydrophilic agents 
may cause rapid release of the active anticancer components in the bloodstream after 
they accumulate in the target lesions; therefore, these agents may not be expected 
to yield persistent and sufficient anticancer drug levels in the plasma against tumor 
growth.4
Miriplatin (Miripla; Dainippon Sumitomo Pharma, Osaka, Japan) is a third-
generation platinum derivative and has been developed recently for transarterial 
treatment of HCC.5 Unlike other hydrophilic anticancer agents, miriplatin contains 
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myristates as lipophilic side chains, which combine with the 
carrier ligand of platinum; therefore, it is easily dissolved in 
iodized oil without the need for emulsification.6 Following 
intra-arterial administration, the miriplatin-iodized oil 
suspension accumulates in the target tumor, and continuous 
antitumor effects caused by gradual release of active platinum 
compounds are expected.6–8 In an early Phase II trial, 56% 
of the patients treated with miriplatin via transarterial 
chemoinfusion therapy were shown to achieve a complete 
response without major adverse events.4 In a randomized late 
Phase II study in patients with unresectable HCC, the mir-
iplatin suspension demonstrated similar therapeutic   efficacy 
to a zinostatin stimalamer suspension; further, it caused less 
hepatic vascular injury than the latter.9 These clinical studies 
suggest that miriplatin is a promising alternative to conven-
tional hydrophilic chemotherapeutic agents such as cisplatin 
or doxorubicin for treating unresectable HCC.
Miriplatin was approved for clinical use and covered by 
public health insurance in Japan in January 2010. Thereafter, 
we initiated the clinical use of miriplatin instead of epirubicin 
hydrochloride (Farmorubicin; Pfizer Japan, Tokyo, Japan) 
for every TACE procedure for treating HCC at our institute. 
In this study, we retrospectively compared the local tumor 
control rate of miriplatin-iodized oil suspension with that of 
epirubicin-iodized oil emulsion and evaluated the prognostic 
factors affecting local tumor progression in the targeted 
TACE for HCC.
Patients and methods
Patients
Consecutive patients with unresectable HCC who had received 
targeted TACE with miriplatin or epirubicin as the sole 
therapy between April 2008 and July 2011 at our institution 
were considered for inclusion in this study. Each patient was 
required to meet the following criteria: no previous treatment 
for the lesions under study, a   Child-Pugh classification of 
A or B, total serum bilirubin level of ,3 mg/dL, no portal 
venous thrombus in the main trunk, no previous history of 
chemotherapy with platinum derivatives, an interval of at 
least 4 weeks after the cessation of any previous anticancer 
therapy, segmental or more distal chemoembolization, and 
no more than three intrahepatic lesions.
Finally, 111 patients with 145 HCC nodules were 
included in this study. The diagnosis of HCC was confirmed 
from previous imaging findings as well as by the elevated 
levels of serum tumor markers. Serum α-fetoprotein level 
of $20 ng/mL and/or serum des-carboxy-prothrombin 
level of $40 mAU/mL were considered as positive tumor 
markers. Serum α-fetoprotein levels were measured by latex 
photometric assay (LPIA 100; Mitsubishikasei, Tokyo, Japan) 
and serum des-carboxy-prothrombin levels were measured 
by the electrochemiluminescence immunoassay method 
(Picolumi PIVKA-II; Eisai, Tokyo, Japan). The detection 
limits for serum α-fetoprotein and des-carboxy-prothrombin 
levels were 2 ng/mL and 5 mAU/mL, respectively. The size 
and number of tumors were determined from the cone-
beam computed tomography (CT) images obtained during 
each TACE session. Because we replaced epirubicin with 
miriplatin for all TACE procedures at our institution from 
June 2010 onwards, 64 patients with 79 lesions received 
epirubicin treatment between April 2008 and June 2010 and 
another 47 patients with 66 lesions received miriplatin treat-
ment between June 2010 and July 2011.
This study was carried out in accordance with the guide-
lines of our institutional review board, and written informed 
consents were obtained from all patients for TACE using 
miriplatin or epirubicin.
Drug preparation
The miriplatin-iodized oil suspension was prepared by 
dissolving 70 mg of miriplatin into 4–5 mL of iodized oil 
(Lipiodol Ultrafluid; Terumo, Tokyo, Japan), while the 
epirubicin-iodized oil emulsion was prepared by dissolving 
10 mg epirubicin into 1 mL of iopamidol (Iopamiron 370; 
Bayer Schering Pharma, Osaka, Japan) and then mixing 
that into 1–2 mL of iodized oil. The maximum dose for a 
single TACE session was limited to 140 mg for miriplatin 
and 50 mg for epirubicin. The actual dose was determined 
based on the size and number of target tumors and the liver 
function of the patient.
Transarterial chemoembolization
All the TACE procedures were performed using the 
same angiographic system (Innova 3100; GE Healthcare, 
Waukesha, WI) by the same two interventional radiologists, 
who have more than 10 years’ experience in hepatic 
vascular interventions. First, an appropriate microcatheter 
was coaxially inserted through a 4-F catheter via the 
femoral artery and placed into the tumor-supplying artery. 
Second, a cone-beam CT image was obtained by injecting 
iopamidol from the microcatheter to confirm whether the 
target tumor was actually located within the treatment area. 
After the tumor location was confirmed, each hepatic area 
containing the target tumors was embolized with gelatin 
particles (Gelpart; Nippon Kayaku, Tokyo, Japan) after 
infusion with the appropriate concentration of chemoth                                                                                                                                                                                                                                                                           
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erapeutic agents. Administration of the drugs and gelatin 
particles was terminated when the tumor vessels were 
completely filled with the drugs and the tumor stain 
disappeared on angiographic imaging.
Treatment evaluation
Seven days after the TACE session, the initial iodized 
oil uptake was assessed by unenhanced CT by using a 
16-multidetector CT scanner (Somatom Sensation; Siemens 
Medical Solutions, Forchheim, Germany). Uptake of 
the iodized oil was graded as good, fair, or poor by a single 
reader, on the basis of its accumulation in the tumor. The 
uptake was scored as good when complete and dense uptake 
occurred throughout the tumor, fair when inhomogeneous 
uptake occurred throughout the tumor, and poor when there 
was evidence of failure of uptake. Only lesions that were 
scored good or fair were included in the study.
Tumor progression was judged using triphasic contrast-
enhanced CT or magnetic resonance (MR) imaging. 
Follow-up CT/MR imaging was performed every 1–3 months, 
depending on previous imaging findings and the laboratory 
data. Recurrence was evaluated by the evidence of abnormal 
early enhancement with washout in the delayed phase of each 
imaging modality.
Statistical analysis
We statistically compared the patient profiles, tumor 
characteristics, and treatment procedures between the miriplatin 
and epirubicin groups using Fisher’s exact test or unpaired 
t test. The local control rate was calculated from the date of 
the TACE session to the last date on which tumor progression 
was documented (or the date of death of the patient). The local 
control rate between the two groups was compared using the 
Kaplan–Meier estimator with log-rank testing. Factors affecting 
local tumor control were first subjected to univariate analysis 
with the log-rank test. The parameters subjected to univariate 
analysis were: patient sex, age, etiology, Child–Pugh class, 
clinical stage, previous treatment history, tumor size, serum 
α-fetoprotein level, serum des-carboxy-prothrombin level, 
treatment area, number of treated tumors, iodized oil dose, 
initial iodized oil uptake, and drug administered. Factors were 
considered statistically significant at P , 0.05. Significant 
factors were subsequently examined by multivariate analysis 
using the Cox proportional hazards model.
Results
We performed targeted TACE for 56 hepatic areas of 
66 HCC nodules in 47 patients of the miriplatin group and 
72 hepatic areas of 79 HCC nodules in 64 patients of the 
epirubicin group. The mean dose of anticancer agents used 
for a single TACE session was 50.5 (range, 10–100) mg 
and 17.5 (range, 5–40) mg for miriplatin and epirubicin, 
respectively. The patient profile, tumor characteristics, and 
treatment procedures in both the groups are summarized 
in Table 1. There were no significant differences in any of 
the parameters investigated between the two study groups. 
Although no significant difference was found, the values 
of the mean iodized oil dose (P = 0.060) and the number 
of treated tumors (P = 0.071) differed between the groups. 
More iodized oil was used and fewer tumors were treated in 
a single TACE session for the miriplatin group compared to 
the epirubicin group.
The median follow-up periods were 150 days (range, 
25–472 days) for subjects receiving miriplatin and 340 days 
(range, 33–1183 days) for those receiving epirubicin. The 
overall recurrence rates were 39.3% (26 of 66 study lesions) 
and 31.6% (25 of 79 study lesions) for the miriplatin and 
epirubicin groups, respectively. The median periods between 
the TACE and local tumor progression were 122.5 days 
(range, 28–459 days) for 26 recurring lesions treated with 
miriplatin and 222 days (range, 33–808 days) for 25 recurring 
lesions treated with epirubicin. The local control rate was 
significantly higher in the epirubicin group than in the 
miriplatin group (log-rank test, P , 0.001) (Figure 1). 
Table  1  Patient  profiles,  tumor  characteristics,  and  treatment 
procedures in the patient groups treated with miriplatin and epirubicin 
in the targeted chemoembolization of hepatocellular carcinoma
Parameters Chemotherapeutic  
agent
P value
Miriplatin Epirubicin
Sex (male/female) 30/17 43/21 0.839
Mean age (years) 70.7 (35–88) 70.1 (48–81) 0.928
Hepatitis (B/C/NBNC) 7/30/10 10/48/6 0.233
Child–Pugh class (A/B) 33/14 46/18 1.000
Clinical stage (I/II/III/IV) 11/32/18/5 16/45/16/2 0.110
Previous treatment 
(primary/recurrence)
25/22 40/24 0.337
Mean tumor size (mm) 17.6 (6–37) 17.6 (7–46) 0.999
Median AFP level (ng/mL) 19 (4–2098) 12 (3–6539) 0.743
Median DCP level (mAU/mL) 92 (6–1810) 93 (5–4760) 0.315
Chemoembolized area  
(segmental/subsegmental/distal)
20/28/8 20/36/16 0.208
Number of treated tumors  
(1/2/3)
30/15/2 51/11/2 0.071
Mean iodized oil dose (mL) 2.9 (0.6–8.0) 2.5 (0.6–6.0) 0.060
Initial iodized oil uptake  
(good/fair)
58/8 66/13 0.488
Notes: Data in brackets denote data range; no statistically significant difference 
was observed between the two groups for any of the parameters. 
Abbreviations: AFP, α-fetoprotein; DCP, des-carboxy-prothrombin.
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The local control rates at 6 months and 1 year were 70.7% 
and 44.8% for the miriplatin group and 83.4% and 69.2% 
for the epirubicin group, respectively. CT images of a tumor 
in a representative case are shown in Figure 2.
The results of the univariate analysis revealed that 
the Child–Pugh class (P = 0.042), serum α-fetoprotein 
  levels (P , 0.001), serum des-carboxy-prothrombin levels 
(P = 0.019), iodized oil dose (P = 0.005), initial iodized oil 
uptake (P = 0.036), and drug administered (P , 0.001) were 
the prognostic factors that significantly affected local tumor 
control. The results of this analysis are presented in Table 2. 
Further, multivariate analysis revealed that the independent 
factors affecting local control rate were the serum 
α-fetoprotein level (,20 ng/mL vs $20 ng/mL; P , 0.001), 
drug administered (epirubicin vs miriplatin; P = 0.002), and 
Child–Pugh class (A vs B; P = 0.042) (Table 3).
Discussion
Miriplatin is a novel anticancer agent that is specifically 
designed for the intraarterial treatment of HCC. This 
highly lipophilic agent is anticipated to exert antitumor 
effects only if it is appropriately delivered in a suspension 
of iodized oil and adequately accumulated in the target site 
over prolonged periods of time. Despite the promising results 
of miriplatin observed in the Phase II trials4,9 as well as the 
early clinical experience with this drug10–12 in TACE for treat-
ing HCC, our study demonstrated that TACE with miriplatin 
had significantly higher local tumor progression than that 
with epirubicin in patients with matched profiles, similar 
tumor characteristics, and treatment procedures. The local 
control rates of a single session of targeted lipiodol-TACE for 
small HCC tumors (,5 cm in diameter) were reported to be 
66.8%–74.4% at 1 year.13,14 These results are comparable to 
the results of our study, where the local control rate of targeted 
TACE for the epirubicin group was 69.2%. It is noteworthy 
that the local control rate of the miriplatin group (44.8%) was 
considerably lower than that of the epirubicin group reported 
in our study and in previous studies.
Recently, a study from Miyayama et al15 reported that the 
local recurrence rate was significantly higher for miriplatin 
compared to epirubicin with mitomycin C in the lipiodol-
based superselective TACE for HCC. The reported local 
control rates for the miriplatin group (5 months, 76.5%; 
10 months, 32.7%) were in compliance with the results 
of our study. Since both of the studies were performed 
independently, the inferiority of miriplatin to epirubicin 
was confirmed from our study. Our study also revealed 
that miriplatin usage was selected as an independent factor 
associated with inferior local control after TACE for HCC 
in the multivariate Cox analysis, and the hazard ratio of 
using miriplatin instead of epirubicin was estimated to be 
2.53 (P = 0.002). This observation has not been presented 
in any previously published reports.
One reason for this poor local tumor control with 
  miriplatin could be the reduced vascular damage caused 
by miriplatin. Miriplatin itself causes less vascular damage 
than zinostatin stimalamer,4 the only oil-soluble anticancer 
agent approved for the intraarterial treatment of HCC in 
Japan. Therefore, repeated use of miriplatin for the same 
hepatic area is clinically feasible without inducing major 
vascular occlusion or arterioportal shunting. On the other 
hand, TACE carried out with an anthracycline anticancer 
agent such as epirubicin or doxorubicin has been reported to 
lead to a high incidence of vascular damage and occlusion of 
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Figure 1 Comparison of the local control rates between the miriplatin (solid line) and epirubicin (dotted line) groups in the targeted chemoembolization of 
hepatocellular carcinoma.
Note: The miriplatin group showed significantly higher local tumor progression as compared to the epirubicin group (P , 0.001).
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the hepatic artery.16,17 Indeed, vascular damage is frequently 
observed in hepatic arteries of the treatment area after 
chemoembolization with epirubicin-iodized oil emulsion, 
hampering subsequent intra-arterial treatment by inducing 
extrahepatic arterial supply to the previously treated lesions. 
However, since some vascular damage may prevent early 
recanalization of tumor vessels and feeders, using miriplatin 
for TACE may result in earlier restoration of blood supply 
to the tumors and earlier washout of the iodized oil from 
the tumor site. To prevent early recanalization of the tumor 
  vessels, it might be useful to add other vascular-toxic anti-
cancer agents in the miriplatin-iodized oil suspension.
Oil suspensions have higher viscosity than water-in-oil 
emulsions. The viscosity of the miriplatin-iodized oil 
suspension may be higher than that of the epirubicin-iodized 
oil emulsion. In addition, we found that the oil droplets of the 
miriplatin-iodized oil suspension delivering to the tumor were 
generally much larger than those of the epirubicin-iodized oil 
suspension. The higher viscosity and larger chemotherapeutic 
droplets of the miriplatin-oil suspension may have resulted in 
unintentional early occlusion of narrow tumor feeders before 
the iodized oil could completely accumulate in the entire 
tumor. Although the level of iodized oil accumulation was 
confirmed on follow-up CT at 1 week after TACE, complete 
distribution of the hyperattenuated area over the treated tumor 
might not imply complete uptake of the iodized oil in the 
entire tumor. Gelatin particles used as an embolic material 
in this study did not obliterate tumor feeders permanently. 
This may be because the embolic material gradually degraded 
in the serum and was absorbed in the plasma over several 
weeks. Some contrast material injected with the gelatin 
particles and/or the iodized oil might have been transiently 
deposited in the lesions until the restoration of blood sup-
ply at the tumor site. Therefore, the therapeutic efficacy of 
the miriplatin-iodized oil suspension might be improved by 
reducing the chemotherapeutic viscosity and further frag-
menting the oil droplets of the mixture, either by emulsifying 
the suspension with a contrast agent or by heating.
Another reason for inferior local tumor control with 
miriplatin may be the low serum platinum concentrations 
due to an excessively slow release of active platinum from 
the tumor site where the miriplatin-iodized oil suspension 
is accumulated. Miriplatin exerts an antitumor effect only 
when active platinum is released from the lipophilic chemi-
cal complex containing myristates as the leaving groups. In 
a previous study on rat hepatic tumors, only 6% of the total 
platinum was reported to be released into the surrounding 
parenchyma at 28 days after intraarterial chemoinfusion of 
miriplatin-iodized oil suspension in the tumors.6 Moreover, 
the total platinum levels in the plasma of patients receiving 
miriplatin at 20–120 mg/body was approximately 300-fold 
lower than those reported in previous studies of intraarterial 
administration of 40–100 mg cisplatin/body.4,18 The maxi-
mum plasma concentration time ranged from 18–37 days 
for the miriplatin study, which was much longer than the 
10–60 minutes observed in the cisplatin study.4 Therefore, 
sufficient plasma concentration of total platinum against the 
tumor progression is expected only when the miriplatin is 
retained in the target tumor for prolonged periods. The total 
platinum levels in the plasma and in the liver parenchyma 
might not have been adequate for the HCC lesions treated 
with miriplatin in this study. Repeated administration of 
miriplatin for the same lesions might increase the level of 
the serum platinum concentration, consequently increasing 
the antitumor effects of miriplatin.
In this study, one patient who received miriplatin in the 
TACE for HCC died of acute interstitial pneumonia 42 days 
after the therapy. The patient had previously been treated with 
Figure 2 Hepatocellular carcinoma (diameter, 32 mm) at hepatic segment II in a 78-year-old man with hepatitis C who underwent chemoembolization using miriplatin. 
(A) Arterial phase image from dynamic contrast-enhanced computed tomography (CT) before chemoembolization delineates a well-enhanced nodular lesion located near 
the inferior vena cava (arrow). (B) Unenhanced CT image obtained 7 days after chemoembolization of arterial segment II + VI shows complete and dense accumulation of 
iodized oil within the entire lesion. (C) Arterial phase image from contrast-enhanced CT 22 weeks after chemoembolization demonstrated that the accumulated iodized oil 
has partially disappeared in the ventral side of the tumor where local tumor recurrence emerged (arrow).
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epirubicin-iodized oil TACE three times for the treatment 
of other HCC lesions. No adverse events were documented 
in the previous TACE procedures with epirubicin, and the 
patient had no history of allergy. The patient received 58 mg 
of miriplatin and 3.3 mL of iodized oil for two intrahepatic 
lesions located at hepatic segment VII and started to complain 
of general fatigue 3 days after the therapy. Miriplatin may 
have caused the acute interstitial pneumonia; however, the 
exact reasons remain unknown because the patient’s family 
did not consent to an autopsy. Eosinophilia is the most fre-
quently observed hematological toxicity of miriplatin.4,10,19 
The eosinophil counts of this patient were not elevated after 
the therapy, but there is a possibility that an allergic reac-
tion toward miriplatin induced acute interstitial pneumonia. 
No other major adverse events were observed in the present 
study, and the hepatic toxicities of both groups were mild 
and within acceptable limits.
There are several merits of using miriplatin in TACE for 
HCC. This third-generation platinum compound does not 
elicit cross-resistance to cisplatin.20 Repeated use of cispla-
tin often causes drug resistance and allergic reactions such 
as anaphylaxis.10,21 The risk of allergic reactions increases 
from the third session of TACE with cisplatin.21 Therefore, 
miriplatin can be considered as a second-line chemoembo-
lization agent in patients who exhibit hypersensitivity or 
resistance to cisplatin. Cisplatin, which is a first-generation 
platinum compound, is associated with renal toxicity, 
whereas miriplatin is known to cause less renal dysfunction 
in comparison,10 suggesting that the latter drug is safe for use 
even in patients with unstable renal function without requir-
ing excessive hydration before and after the therapy. Further, 
the use of miriplatin is associated with fewer adverse events 
as compared to cisplatin, including nausea, appetite loss, 
pain, anorexia, and fever.10 Combining miriplatin and other 
anticancer agents would potentially enhance the therapeutic 
efficacy of miriplatin and reduce probable adverse effects.
Conclusion
In conclusion, TACE for HCC using a miriplatin-iodized 
oil suspension resulted in inferior local tumor control 
compared with an epirubicin-iodized oil emulsion in 
patients with matched profiles, tumor characteristics, and 
Table 2 Univariate analysis of prognostic factors affecting local 
tumor progression for 111 patients with 145 tumors
Parameters Number  
(n = 145)
Local control rate  
(%)
P value
6 months 1 year
Sex 
  Male 
  Female
 
100 
45
 
79.8 
72.6
 
60.0 
53.8
0.604
Age 
  ,70 
  $70
 
54 
91
 
72.2 
79.2
 
54.8 
62.2
0.662
Etiology 
  HBV/HCV 
  Others
 
127 
18
 
77.8 
82.5
 
58.3 
47.1
0.602
Child–Pugh class 
 A  
 B
 
100 
45
 
85.9 
55.4
 
61.6 
46.2
0.042*
Clinical stage 
  I/II 
  III/IV
 
104 
41
 
78.2 
75.7
 
61.1 
54.8
0.770
Previous treatment 
  Primary 
  Recurrence
 
57 
88
 
77.6 
77.1
 
66.1 
54.9
0.381
Tumor size 
  ,2 cm 
  $2 cm
 
99 
46
 
81.4 
69.6
 
63.5 
51.0
0.088
Serum AFP level 
  ,20 ng/mL 
  $20 ng/mL
 
81 
64
 
89.1 
61.6
 
72.1 
42.1
,0.001*
Serum DCP level 
  ,40 mAU/mL 
  $40 mAU/mL
 
50 
95
 
93.7 
69.5
 
69.0 
54.1
0.019*
Treatment area 
    Segmental 
Subsegmental/distal
 
58 
87
 
75.0 
78.9
 
52.0 
63.1
0.371
Number of treated tumors 0.175
 1  
  2/3
81 
64
82.1 
74.3
64.5 
55.8
Iodized oil dose 
  ,3 mL 
  $3 mL
 
79 
66
 
88.8 
66.0
 
65.0 
53.3
0.005*
Initial iodized oil uptake 0.036*
  good 
  Fair
121 
24
80.3 
69.6
63.0 
37.2
Drug 
  Epirubicin 
  Miriplatin
 
79 
66
 
83.4 
70.7
 
69.2 
44.8
,0.001*
Notes: *The Child–Pugh class, serum AFP level, serum DCP level, iodized oil dose, 
initial iodized oil uptake, and drug administered were selected as the significant 
prognostic  factors  affecting  local  tumor  progression.  Abbreviations:  AFP, 
α-fetoprotein; HBV, hepatitis B virus; DCP, des-carboxy-prothrombin; HCV, hepatitis 
C virus.
Table 3 Multivariate analysis of prognostic factors affecting local 
tumor progression
Parameters Hazard ratio P value
Child–Pugh class (A vs B) 1.89 (1.02–3.53) 0.042*
AFP (,20 ng/mL vs $20 ng/mL) 2.96 (1.66–5.26) ,0.001*
DCP (,40 mAU/mL vs $40 mAU/mL) 1.61 (0.84–3.10) 0.151
Iodized oil dose (,3 mL vs $3 mL) 1.57 (0.83–2.97) 0.162
Initial iodized oil uptake (good vs fair) 1.87 (0.94–3.69) 0.069
Drug (epirubicin vs miriplatin) 2.53 (1.38–4.62) 0.002*
Notes: Data in brackets denote 95% confidence intervals; *Child–Pugh class, serum 
AFP level, and administered drug were the significant independent factors affecting 
local tumor progression.
Abbreviations: AFP, α-fetoprotein; DCP, des-carboxy-prothrombin.
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treatment procedures. In the multivariate Cox proportional 
analysis, miriplatin usage for TACE for HCC was found 
to be an independent factor associated with inferior local 
control rate bearing a hazard ratio of 2.53 when compared to 
epirubicin usage. However, further investigation is required 
to evaluate the long-term therapeutic efficacy of miriplatin.
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